Puma Biotechnology (PBYI) stock tumbled Thursday after the company released disappointing data late Wednesday, ahead of the annual American Society for Clinical Oncology meeting. The ASCO abstract release also featured positive but somewhat conflicting news on new immuno-oncology drugs from Roche (RHHBY), AstraZeneca (AZN) and Merck (MRK). Puma issued results of its late-stage trial of breast-cancer drug neratinib, whose earlier results were so
New FDA documents released Friday said patients on popular AstraZeneca (AZN) diabetes drug Onglyza show an increased risk of death. AstraZeneca’s stock fell 2% in early trading. The briefing documents came out ahead of an advisory committee panel convening Tuesday to evaluate the safety of Onglyza (generically called saxagliptin) and a similar drug, Takeda’s Nesina, in light of two cardiovascular (CV) outcomes trials called Savor and Examine,
Regulus Therapeutics (RGLS) stock leapt Tuesday night as AstraZeneca (AZN) took its NASH fatty liver disease candidate for testing as part of their microRNA alliance. They join a crowded field of drugmakers developing treatments and making investments to get part of NASH, a form of liver damage caused by accumulation of fat. Regulus said RG-125, a compound to treat nonalcoholic steatohepatitis (NASH) in patients with type II diabetes or